In a notable update from the FDA, the agency has been actively designating a growing number of generative AI devices as 'breakthrough' technologies. This designation is intended to expedite the development and review processes for devices that may offer significant benefits.
Additionally, the FDA has decided to drop enforcement actions against Whoop, a company known for its health tracking devices. This move suggests a possible shift in regulatory approach regarding wearable technology.
The expansion of the FDA's breakthrough pipeline reflects an increasing recognition of the potential impact of AI in healthcare, though the implications of these changes are still unfolding.